Almac Group Launches US Serialisation Solution
News May 12, 2016
Almac Group has announced an expansion to its serialisation capabilities to include its US commercial packaging facility in Audubon, PA. Building upon Almac’s in-house expertise and proprietary serialisation / track and trace solution developed at its UK headquarters, this technology expansion will address FDA regulations meeting the requirements outlined in the Drug Quality and Security Act together with meeting client demand for a local US, flexible, contract packaging serialisation provider.
Having assessed multiple vendors, Almac partnered with Optel Vision to provide a versatile line level solution (hardware and software) that integrated with Almac’s in-house proprietary level 3, site level software. This new serialisation solution is a high-spec standalone line that prints, verifies and aggregates saleable packs through to the pallet with reporting functionality to ensure the client can meet the traceability requirements of the various markets.
Grainne Hughes, Operations Manager at Almac explains “Having built our own serialisation line for the UK operations some years ago we developed a strong knowledge base. To expand the solution into our US operations we decided that we needed an experienced partner that could integrate with our innovative product serialisation site level software. The partnership with Optel Vision has provided our US commercial packaging facility with a truly flexible and adaptable solution to readily meet specific country, market and client requirements whilst ensuring serialisation to GS1 Standards.”
“We knew Almac had its own in-house solution for the UK and for the first Almac serialisation project in the US, we combined the knowledge of both companies to design a solution that meets Almac quality standards as well as the demand from global markets using the Optel Vision hardware and software solutions. The system is now operational and can be easily scalable for future needs.” says Yvon Lemay, Optel Vision Project Manager.
Almac US can now offer the flexibility to our Clients to serialise as part of the pack process, as part of a repackaging exercise, or as a stand-alone serialisation application to already packed product.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019